Table 2.

Best overall response by ICI.

	CR	PR	SD	PD	NE	ORR*	DCR**	CBR†
Nivolumab (n=4)	1	1	0	1	1	50.0%	50.0%	50.0%
Pembrolizumab (n=2)	0	0	2	0	0	0%	100%	0%
Total (n=6)	1	1	2	1	1	33.3%	66.7%	33.3%

^*Proportion of CR + PR. ^**Proportion of CR + PR + SD. ^†Proportion of CR + PR + SD at 6 months.

ICI, immune checkpoint inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; DCR, disease control rate; and CBR, clinical benefit rate.